Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nurr1 siRNA
- Development stage
- Preclinical
- Lead developer
- The University of Hong Kong
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intrathecal
01
Overview
Nurr1 siRNA is a small interfering RNA designed to silence the expression of the orphan nuclear receptor Nurr1 (NR4A2). In the context of oncology research, particularly cervical cancer, Nurr1 has been identified as a potential oncogenic target that promotes cell proliferation, migration, and spheroid formation while inhibiting apoptosis. By utilizing RNA interference (RNAi), Nurr1 siRNA mediates the degradation of Nurr1 mRNA, leading to reduced protein levels and subsequent attenuation of cancer progression. Research conducted at the University of Hong Kong has demonstrated that silencing Nurr1 increases the expression of pro-apoptotic and tumor suppressor genes such as Bim and p21, suggesting its role in modulating the transcription of genes involved in cell death and growth arrest.
- Other names
- NR4A2 siRNANR-4A2 siRNANR 4A2 siRNANuclear receptor related 1 siRNA
02
Targets
NR4A2 (Nuclear receptor subfamily 4 group A member 2)
Beyond the preview
Go deeper on Nurr1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nurr1 siRNA.